STOCK TITAN

[8-K] Cytosorbents Corp. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

MGIC Investment Corp. (MTG) – Form 4 insider transaction

President & COO Salvatore A. Miosi disclosed the sale of 30,000 shares of common stock on 01-Jul-2025 at a weighted-average price of $28.152 per share, generating roughly $0.84 million in proceeds. The disposition was executed under a Rule 10b5-1 trading plan adopted on 06-Mar-2025, indicating the sale was pre-scheduled and not necessarily driven by near-term information.

After the transaction, Miosi directly owns 279,401.361 shares and indirectly controls 384,844 shares via a family trust, maintaining a sizable equity stake. No derivative security activity was reported, and the filing contains no references to earnings, major corporate events, or strategic changes.

The filing primarily records a routine adjustment to the executive’s equity exposure; in isolation, it is unlikely to materially affect the company’s fundamental outlook.

MGIC Investment Corp. (MTG) – Transazione interna Form 4

Il Presidente e COO Salvatore A. Miosi ha comunicato la vendita di 30.000 azioni ordinarie il 01-lug-2025 a un prezzo medio ponderato di 28,152$ per azione, generando circa 0,84 milioni di dollari di ricavi. L'operazione è stata eseguita nell'ambito di un piano di trading Rule 10b5-1 adottato il 06-mar-2025, indicando che la vendita era programmata in anticipo e non necessariamente basata su informazioni recenti.

Dopo la transazione, Miosi detiene direttamente 279.401,361 azioni e controlla indirettamente 384.844 azioni tramite un trust familiare, mantenendo una quota azionaria significativa. Non sono state segnalate attività su strumenti derivati e il documento non fa riferimento a utili, eventi societari rilevanti o cambiamenti strategici.

La comunicazione registra principalmente un aggiustamento di routine dell'esposizione azionaria dell'esecutivo; isolatamente, è improbabile che influenzi in modo sostanziale le prospettive fondamentali dell'azienda.

MGIC Investment Corp. (MTG) – Transacción interna Formulario 4

El Presidente y COO Salvatore A. Miosi reveló la venta de 30,000 acciones ordinarias el 01-jul-2025 a un precio promedio ponderado de $28.152 por acción, generando aproximadamente $0.84 millones en ingresos. La operación se realizó bajo un plan de negociación Rule 10b5-1 adoptado el 06-mar-2025, lo que indica que la venta fue programada con anticipación y no necesariamente motivada por información reciente.

Tras la transacción, Miosi posee directamente 279,401.361 acciones y controla indirectamente 384,844 acciones a través de un fideicomiso familiar, manteniendo una participación accionaria considerable. No se reportó actividad con valores derivados y el documento no menciona ganancias, eventos corporativos importantes ni cambios estratégicos.

El informe registra principalmente un ajuste rutinario en la exposición accionaria del ejecutivo; aisladamente, es poco probable que afecte materialmente las perspectivas fundamentales de la empresa.

MGIC Investment Corp. (MTG) – Form 4 내부자 거래

사장 겸 COO인 Salvatore A. Miosi는 2025년 7월 1일에 보통주 30,000주를 주당 가중평균 가격 28.152달러에 매도하여 약 84만 달러의 수익을 올렸다고 공시했습니다. 이 매도는 2025년 3월 6일 채택된 Rule 10b5-1 거래 계획에 따라 사전에 예약된 거래임을 의미하며, 단기 정보에 따른 결정은 아닙니다.

거래 후 Miosi는 직접 279,401.361주를 보유하고 있으며, 가족 신탁을 통해 간접적으로 384,844주를 통제하여 상당한 지분을 유지하고 있습니다. 파생상품 관련 활동은 보고되지 않았으며, 제출 서류에는 수익, 주요 기업 이벤트 또는 전략적 변경에 대한 언급이 없습니다.

이번 공시는 경영진의 지분 노출에 대한 일상적인 조정 사항을 기록한 것으로, 단독으로 회사의 근본적인 전망에 중대한 영향을 미칠 가능성은 낮습니다.

MGIC Investment Corp. (MTG) – Transaction d’initié Formulaire 4

Le Président et COO Salvatore A. Miosi a déclaré la vente de 30 000 actions ordinaires le 01-juil-2025 à un prix moyen pondéré de 28,152 $ par action, générant environ 0,84 million de dollars de revenus. La cession a été réalisée dans le cadre d’un plan de trading Rule 10b5-1 adopté le 06-mars-2025, indiquant que la vente était programmée à l’avance et n’était pas nécessairement motivée par des informations récentes.

Après la transaction, Miosi détient directement 279 401,361 actions et contrôle indirectement 384 844 actions via une fiducie familiale, conservant ainsi une participation significative. Aucune activité sur titres dérivés n’a été signalée et le dépôt ne fait référence ni aux bénéfices, ni à des événements majeurs de l’entreprise, ni à des changements stratégiques.

Le dépôt enregistre principalement un ajustement de routine de l’exposition en actions de l’exécutif ; pris isolément, il est peu probable qu’il affecte de manière significative les perspectives fondamentales de l’entreprise.

MGIC Investment Corp. (MTG) – Insider-Transaktion Form 4

Präsident und COO Salvatore A. Miosi meldete den Verkauf von 30.000 Stammaktien am 01. Juli 2025 zu einem gewichteten Durchschnittspreis von 28,152 $ pro Aktie, was etwa 0,84 Millionen $ Erlös generierte. Die Veräußerung erfolgte im Rahmen eines Rule 10b5-1 Handelsplans, der am 06. März 2025 angenommen wurde, was darauf hinweist, dass der Verkauf vorab geplant war und nicht unbedingt durch kurzfristige Informationen getrieben wurde.

Nach der Transaktion besitzt Miosi direkt 279.401,361 Aktien und kontrolliert indirekt 384.844 Aktien über einen Familientrust, wodurch er eine bedeutende Beteiligung hält. Es wurden keine Aktivitäten mit Derivaten gemeldet, und die Einreichung enthält keine Hinweise auf Gewinne, bedeutende Unternehmensereignisse oder strategische Veränderungen.

Die Meldung dokumentiert hauptsächlich eine routinemäßige Anpassung der Aktienexponierung des Geschäftsführers; isoliert betrachtet wird dies voraussichtlich keine wesentlichen Auswirkungen auf die fundamentalen Aussichten des Unternehmens haben.

Positive
  • Sale executed under a Rule 10b5-1 plan, reducing concerns about opportunistic insider trading.
  • Executive retains significant ownership—279,401 direct and 384,844 indirect shares—maintaining alignment with shareholders.
Negative
  • Disposition of 30,000 shares by the President & COO represents a cash realisation of roughly $0.84 million.
  • Direct ownership dilution may be interpreted by some investors as a mildly negative sentiment signal.

Insights

TL;DR Pre-planned 30k-share sale by MTG COO is modest and leaves large stake; overall market impact neutral.

The transaction represents approximately 4–5 % of the executive’s combined direct and indirect holdings. Because it was carried out under a Rule 10b5-1 plan, the signalling value is limited. Proceeds of roughly $0.84 million suggest personal diversification rather than a statement on valuation. With no derivative activity or concurrent corporate news, I view the filing as routine and not a catalyst for valuation change.

TL;DR Scheduled sale aligns with governance best practices; minor share reduction poses low governance risk.

Utilising a pre-established 10b5-1 plan mitigates concerns about selective disclosure or opportunistic trading and demonstrates compliance discipline. The officer still holds over 660k shares, maintaining strong alignment with shareholder interests. From a governance perspective, the event is non-problematic and should not influence proxy advisory stances.

MGIC Investment Corp. (MTG) – Transazione interna Form 4

Il Presidente e COO Salvatore A. Miosi ha comunicato la vendita di 30.000 azioni ordinarie il 01-lug-2025 a un prezzo medio ponderato di 28,152$ per azione, generando circa 0,84 milioni di dollari di ricavi. L'operazione è stata eseguita nell'ambito di un piano di trading Rule 10b5-1 adottato il 06-mar-2025, indicando che la vendita era programmata in anticipo e non necessariamente basata su informazioni recenti.

Dopo la transazione, Miosi detiene direttamente 279.401,361 azioni e controlla indirettamente 384.844 azioni tramite un trust familiare, mantenendo una quota azionaria significativa. Non sono state segnalate attività su strumenti derivati e il documento non fa riferimento a utili, eventi societari rilevanti o cambiamenti strategici.

La comunicazione registra principalmente un aggiustamento di routine dell'esposizione azionaria dell'esecutivo; isolatamente, è improbabile che influenzi in modo sostanziale le prospettive fondamentali dell'azienda.

MGIC Investment Corp. (MTG) – Transacción interna Formulario 4

El Presidente y COO Salvatore A. Miosi reveló la venta de 30,000 acciones ordinarias el 01-jul-2025 a un precio promedio ponderado de $28.152 por acción, generando aproximadamente $0.84 millones en ingresos. La operación se realizó bajo un plan de negociación Rule 10b5-1 adoptado el 06-mar-2025, lo que indica que la venta fue programada con anticipación y no necesariamente motivada por información reciente.

Tras la transacción, Miosi posee directamente 279,401.361 acciones y controla indirectamente 384,844 acciones a través de un fideicomiso familiar, manteniendo una participación accionaria considerable. No se reportó actividad con valores derivados y el documento no menciona ganancias, eventos corporativos importantes ni cambios estratégicos.

El informe registra principalmente un ajuste rutinario en la exposición accionaria del ejecutivo; aisladamente, es poco probable que afecte materialmente las perspectivas fundamentales de la empresa.

MGIC Investment Corp. (MTG) – Form 4 내부자 거래

사장 겸 COO인 Salvatore A. Miosi는 2025년 7월 1일에 보통주 30,000주를 주당 가중평균 가격 28.152달러에 매도하여 약 84만 달러의 수익을 올렸다고 공시했습니다. 이 매도는 2025년 3월 6일 채택된 Rule 10b5-1 거래 계획에 따라 사전에 예약된 거래임을 의미하며, 단기 정보에 따른 결정은 아닙니다.

거래 후 Miosi는 직접 279,401.361주를 보유하고 있으며, 가족 신탁을 통해 간접적으로 384,844주를 통제하여 상당한 지분을 유지하고 있습니다. 파생상품 관련 활동은 보고되지 않았으며, 제출 서류에는 수익, 주요 기업 이벤트 또는 전략적 변경에 대한 언급이 없습니다.

이번 공시는 경영진의 지분 노출에 대한 일상적인 조정 사항을 기록한 것으로, 단독으로 회사의 근본적인 전망에 중대한 영향을 미칠 가능성은 낮습니다.

MGIC Investment Corp. (MTG) – Transaction d’initié Formulaire 4

Le Président et COO Salvatore A. Miosi a déclaré la vente de 30 000 actions ordinaires le 01-juil-2025 à un prix moyen pondéré de 28,152 $ par action, générant environ 0,84 million de dollars de revenus. La cession a été réalisée dans le cadre d’un plan de trading Rule 10b5-1 adopté le 06-mars-2025, indiquant que la vente était programmée à l’avance et n’était pas nécessairement motivée par des informations récentes.

Après la transaction, Miosi détient directement 279 401,361 actions et contrôle indirectement 384 844 actions via une fiducie familiale, conservant ainsi une participation significative. Aucune activité sur titres dérivés n’a été signalée et le dépôt ne fait référence ni aux bénéfices, ni à des événements majeurs de l’entreprise, ni à des changements stratégiques.

Le dépôt enregistre principalement un ajustement de routine de l’exposition en actions de l’exécutif ; pris isolément, il est peu probable qu’il affecte de manière significative les perspectives fondamentales de l’entreprise.

MGIC Investment Corp. (MTG) – Insider-Transaktion Form 4

Präsident und COO Salvatore A. Miosi meldete den Verkauf von 30.000 Stammaktien am 01. Juli 2025 zu einem gewichteten Durchschnittspreis von 28,152 $ pro Aktie, was etwa 0,84 Millionen $ Erlös generierte. Die Veräußerung erfolgte im Rahmen eines Rule 10b5-1 Handelsplans, der am 06. März 2025 angenommen wurde, was darauf hinweist, dass der Verkauf vorab geplant war und nicht unbedingt durch kurzfristige Informationen getrieben wurde.

Nach der Transaktion besitzt Miosi direkt 279.401,361 Aktien und kontrolliert indirekt 384.844 Aktien über einen Familientrust, wodurch er eine bedeutende Beteiligung hält. Es wurden keine Aktivitäten mit Derivaten gemeldet, und die Einreichung enthält keine Hinweise auf Gewinne, bedeutende Unternehmensereignisse oder strategische Veränderungen.

Die Meldung dokumentiert hauptsächlich eine routinemäßige Anpassung der Aktienexponierung des Geschäftsführers; isoliert betrachtet wird dies voraussichtlich keine wesentlichen Auswirkungen auf die fundamentalen Aussichten des Unternehmens haben.

false 0001175151 0001175151 2025-07-02 2025-07-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): July 2, 2025

 

CYTOSORBENTS CORPORATION

(Exact name of registrant as specified in its charter) 

 

Delaware   001-36792   98-0373793
(State or other jurisdiction of
incorporation)
  (Commission File Number)   (I.R.S. Employer Identification No.)

 

305 College Road East

Princeton, New Jersey

08540
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (732) 329-8885

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common Stock, $0.001 par value CTSO The Nasdaq Stock Market LLC (Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 8.01 Other Events.

 

On July 2, 2025, CytoSorbents Corporation (the “Company”) issued a press release announcing, among other items, that the U.S. Food and Drug Administration has scheduled an appeal hearing date for the Company’s supervisory review under 21 CFR 10.75 and that Health Canada issued a Notice of Refusal of the Company’s Medical Device License application, citing non-compliance with certain Medical Devices Regulations. The Company intends to file a Level 1 “Request for Reconsideration” with the Medical Devices Directorate Bureau Director by July 25, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

 

Item 9.01Exhibits.

 

(d) Exhibits

 

Exhibit No. Description
99.1 Press Release of the Company, dated July 2, 2025
104 Cover Page Interactive Data File (embedded with the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: July 2, 2025 CYTOSORBENTS CORPORATION
     
  By: /s/ Dr. Phillip P. Chan
  Name: Dr. Phillip P. Chan
  Title: Chief Executive Officer

 

 

FAQ

How many MGIC (MTG) shares did President & COO Salvatore Miosi sell on 1 Jul 2025?

He sold 30,000 shares of MGIC common stock.

At what price were the MTG shares sold according to the Form 4?

The weighted-average sale price was $28.152 per share, with trades ranging from $27.80 to $28.34.

What trading plan covered the MTG insider sale disclosed on July 1, 2025?

The sale was executed under a Rule 10b5-1 trading plan adopted on 06-Mar-2025.

How many MGIC shares does Salvatore Miosi own after the transaction?

He owns 279,401.361 shares directly and 384,844 shares indirectly through a family trust.

Is any derivative security activity reported in this MTG Form 4?

No derivative securities were acquired or disposed of; Table II is blank.

When was the Rule 10b5-1 plan adopted by the MTG executive?

The plan was adopted on 06-Mar-2025.
Cytosorbents Corp

NASDAQ:CTSO

CTSO Rankings

CTSO Latest News

CTSO Latest SEC Filings

CTSO Stock Data

75.13M
53.25M
9.72%
29.71%
2.97%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
PRINCETON